SCHEMBL2804418

SCHEMBL2804418

O=C(O)c1cccc2c1NC(C(=O)O)C1CC=CC21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 1/20 1.00
PTPN7 P35236 12/20 0.81
HSPA1A P0DMV8 8/20 0.81
HSPA8 P11142 6/20 0.81
CD44 P16070 1/20 0.81
MSN P26038 1/20 0.81
GAPDH P04406 5/20 0.74
TDP1 Q9NUW8 5/20 0.74
KDM4E B2RXH2 4/20 0.74
MEN1 O00255 4/20 0.74
POLB P06746 4/20 0.74
MAPT P10636 4/20 0.74
KMT2A Q03164 4/20 0.74
HSD17B10 Q99714 4/20 0.74
L3MBTL1 Q9Y468 4/20 0.74
RECQL P46063 3/20 0.74
BLM P54132 3/20 0.74
THRB P10828 2/20 0.74
CACNA1B Q00975 2/20 0.74
APBA1 Q02410 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14758490 1.00 CDC25B (1.00) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL13726071 0.90 PTPN7 (1.00) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL14758432 0.88 CDC25B (0.78) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL13726075 0.87 CDC25B (0.76) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL2116061 0.85 PTPN7 (1.00) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL13725212 0.85 PTPN7 (0.88) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL13856219 0.85 NR4A1 (1.00) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL13725249 0.85 CDC25B (0.73) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL14680373 0.84 PTPN7 (1.00) CDC25BPTPN7HSPA1AHSPA8CD44
SCHEMBL13725247 0.84 CDC25B (0.71) CDC25BPTPN7HSPA1AHSPA8CD44

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-11559474-B2 Hair lightening compositions and methods of use L'OREAL (FR) 2023-01-24 US disclosed
WO-2018119500-A1 VISCOELASTIC COSMETIC COMPOSITIONS L'OREAL (FR) 2018-07-05 WO disclosed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US disclosed
US-20140329863-A1 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-11-06 US disclosed
WO-2013033037-A2 NOVEL ANTIPRION COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-03-07 WO disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090203726-A1 SUBSTITUTED TETRAHYDROQUINOLINES AS ANTIBACTERIAL AGENTS MAXTHERA INC. (US) 2009-08-13 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329863-A1 NOVEL ANTIPRION COMPOUNDS PRNP, PSEN1, PSEN2 CDC25B 4790/4885PTPN7 4612/4885HSPA1A 534/4885
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 CDC25B 531/4885PTPN7 1180/4885HSPA1A 1414/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB CDC25B 1533/4885PTPN7 1673/4885HSPA1A 3324/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA CDC25B 1438/4885PTPN7 1432/4885HSPA1A 2508/4885
US-20090203726-A1 SUBSTITUTED TETRAHYDROQUINOLINES AS ANTIBACTERIAL AGENTS NISCH, NDUFS3, SDHA CDC25B 1626/4885PTPN7 3898/4885HSPA1A 581/4885
US-11559474-B2 Hair lightening compositions and methods of use TYR, ALAD, CYBA CDC25B 2766/4885PTPN7 1408/4885HSPA1A 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.